APA (7th ed.) Citation

J, H., J, A., S, W., K, P., ZC, O., H, W., . . . S, C. (2023). Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis. Targeted oncology, 18(4), 593. https://doi.org/10.1007/s11523-023-00972-8

Chicago Style (17th ed.) Citation

J, Heseltine, et al. "Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis." Targeted Oncology 18, no. 4 (2023): 593. https://doi.org/10.1007/s11523-023-00972-8.

MLA (9th ed.) Citation

J, Heseltine, et al. "Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis." Targeted Oncology, vol. 18, no. 4, 2023, p. 593, https://doi.org/10.1007/s11523-023-00972-8.